These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8562379)

  • 1. Interleukin 2 in the management of acute leukaemia.
    Foa R
    Br J Haematol; 1996 Jan; 92(1):1-8. PubMed ID: 8562379
    [No Abstract]   [Full Text] [Related]  

  • 2. Has IL2 a role in the management of minimal residual disease for acute leukemia?
    Foa R; Meloni G; Guarini A; Mandelli F; Gavosto F
    Leukemia; 1992 Nov; 6 Suppl 4():92-4. PubMed ID: 1434844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 in the treatment of acute leukemia.
    Blaise D; Maraninchi D
    Leuk Res; 1998 Dec; 22(12):1165-70. PubMed ID: 9922080
    [No Abstract]   [Full Text] [Related]  

  • 4. Does interleukin-2 have a role in the management of acute leukemia?
    Foa R
    J Clin Oncol; 1993 Sep; 11(9):1817-25. PubMed ID: 8355048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression.
    Cignetti A; Guarini A; Carbone A; Forni M; Cronin K; Forni G; Gansbacher B; Foa R
    J Natl Cancer Inst; 1994 May; 86(10):785-91. PubMed ID: 8169977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
    Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan KW; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
    Cytokines Mol Ther; 1995 Jun; 1(2):115-22. PubMed ID: 9384668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma.
    Stewart AK; Lassam NJ; Graham FL; Gauldie J; Addison CL; Bailey DJ; Dessureault S; Dubé ID; Gallenger S; Krajden M; Rotstein LE; Quirt IC; Moen R
    Hum Gene Ther; 1997 Jul; 8(11):1403-14. PubMed ID: 9295135
    [No Abstract]   [Full Text] [Related]  

  • 8. [The role of interleukin-2--based immunotherapy in hematological malignancies].
    Ackerstein A; Toren A; Slavin S; Nagler A
    Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of minimal residual disease in acute leukemia--focus on immunotherapeutic options.
    Simonsson B; Nilsson BI; Rowe JM
    Leukemia; 1992 Nov; 6 Suppl 4():124-34. PubMed ID: 1279326
    [No Abstract]   [Full Text] [Related]  

  • 10. Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion.
    Lim SH; Callaghan T; Goldstone AH
    Acta Haematol; 1991; 85(1):49-50. PubMed ID: 2011933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
    Caporaso P; Turriziani M; Venditti A; Marchesi F; Buccisano F; Tirindelli MC; Alvino E; Garbin A; Tortorelli G; Toppo L; Bonmassar E; D'Atri S; Amadori S
    DNA Repair (Amst); 2007 Aug; 6(8):1179-86. PubMed ID: 17500047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do BMTs cure leukaemia? New directions.
    Prentice HG
    Bone Marrow Transplant; 1991; 7 Suppl 2():11-3. PubMed ID: 1878667
    [No Abstract]   [Full Text] [Related]  

  • 13. Possible application of natural killer cells and interleukin-2 in therapy of human leukemia.
    Lotzová E
    Prog Clin Biol Res; 1987; 244():259-66. PubMed ID: 3498951
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
    Dutcher JP; Wiernik PH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
    Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
    [No Abstract]   [Full Text] [Related]  

  • 16. Amplification of the graft-versus-leukemia effect in man by interleukin-2.
    Verdonck LF; van Heugten HG; Giltay J; Franks CR
    Transplantation; 1991 May; 51(5):1120-4. PubMed ID: 2031266
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-2 in therapy of hematologic malignancies.
    Sznol M; Parkinson DR
    Blood; 1994 Apr; 83(8):2020-2. PubMed ID: 8161773
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes MC; Massumoto C; Higuchi C; York A; Buckner CD; Thompson JA
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):41-5. PubMed ID: 8284691
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-2 therapy of cancer.
    Bubeník J
    Folia Biol (Praha); 2004; 50(3-4):120-30. PubMed ID: 15373345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma.
    Hum Gene Ther; 1992 Dec; 3(6):677-90. PubMed ID: 1482708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.